Windlas Biotech Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Windlas Biotech reported its highest ever quarterly revenue of Rs 248 crore in Q1 FY27, up 18% year-on-year, marking 14 consecutive quarters of record revenue. The Generic Formulations CDMO vertical grew 29% year-on-year while Trade Generics & Institutional revenue declined following discontinuation of codeine-based products, and Exports grew 79% year-on-year. Management said Plant 6 remains on track for commercialization in H1 FY27 and discussed capacity, working capital and API price volatility during the quarter.
Windlas Biotech reported FY26 revenue of INR904 crores, up 19% year-on-year, with Q4 FY26 revenue at INR238 crores, up 18% year-on-year, marking 13 consecutive quarters of record revenue. Management attributed growth to the CDMO vertical, which grew 20% year-on-year, while the Trade Generics and Institutional vertical faced softness from the exit of codeine-based cough syrups. The company also reported completion of a buyback, a proposed dividend, and progress on Plant 6, which reached mechanical completion and is expected to commercialize in H1 FY27.